We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Research · September 28, 2022

Upadacitinib vs Adalimumab as Initial Therapy for Achieving 48-Week Treatment Goals in Patients With Rheumatoid Arthritis

Rheumatology (Oxford, England)


Additional Info

Rheumatology (Oxford, England)
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
Rheumatology (Oxford) 2022 Aug 26;[EPub Ahead of Print], E Mysler, Y Tanaka, A Kavanaugh, D Aletaha, PC Taylor, IH Song, T Shaw, Y Song, R DeMasi, M Ali, R Fleischmann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading